GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Accumulated Depreciation

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Accumulated Depreciation : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Clinuvel Pharmaceuticals's quarterly accumulated depreciation increased from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($-1.58 Mil) but then stayed the same from Jun. 2023 ($-1.58 Mil) to Dec. 2023 ($0.00 Mil).

Clinuvel Pharmaceuticals's annual accumulated depreciation increased from Jun. 2021 ($-0.77 Mil) to Jun. 2022 ($-1.17 Mil) and increased from Jun. 2022 ($-1.17 Mil) to Jun. 2023 ($-1.58 Mil).


Clinuvel Pharmaceuticals Accumulated Depreciation Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Accumulated Depreciation Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.24 -0.52 -0.77 -1.17 -1.58

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1.17 - -1.58 -

Clinuvel Pharmaceuticals Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.


Clinuvel Pharmaceuticals Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Headlines

From GuruFocus

CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

By Stock market mentor Stock market mentor 02-02-2023

CLINUVEL Opens VALLAURIX R&D Centre In Singapore

By Marketwired Marketwired 08-31-2020

CLINUVEL to Trial Innovative Drug in Stroke

By Marketwired Marketwired 10-28-2020

Positive final results in stroke

By GuruFocusNews GuruFocusNews 05-04-2022

CLINUVEL delivers second positive financial result

By Marketwired Marketwired 08-29-2018

US FDA sets PDUFA date for SCENESSE®

By Marketwired Marketwired 01-10-2019

CLINUVEL Launches CYAC�LLE, Next Generation Solar Care

By sperokesalga sperokesalga 03-01-2023

Letter to shareholders from CLINUVEL's CEO

By GuruFocusNews GuruFocusNews 04-29-2022